Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.

Period	PE Ratio
2015-12-31	N/A
2016-12-31	N/A
2017-12-31	N/A
2018-12-31	N/A
2019-12-31	N/A
2020-12-31	-1.51
2021-12-31	N/A
2022-12-31	N/A
2023-12-31	-2.17
2024-12-31	-2.52

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VANI	$1.08	+2.36%	0.06M
3
4
5

Vivani Medical Inc. (VANI) PE Ratio

PE Ratio Data

Get Vivani Medical Inc. Data in Excel

More VANI Financial Data